The identification and validation of biomarkers of AMI-CS sub-phenotypes, such as bio-adrenomedullin for severe or refractory vasoplegia [118], raises the enticing prospect of future targeted therapies across a range of shock states including AMI-CS. The gene discussed is ADM; the disease is Cowden syndrome 1.